Sanofi Experimental Drug Helps Patients With Bowel Disease

Sanofi said an experimental medicine it’s developing with Teva Pharmaceuticals Inc. helped patients with inflammatory bowel disease.

The benefits after treatment with the drug, duvakitug, were maintained over 44 weeks, Sanofi said in a statement. The 130 patients enrolled in the intermediate trial had ulcerative colitis or Crohn’s disease.